Wednesday, July 8, 2026

pharma · Cocaine-Related Disorders · Cocaine Dependence · DRUG

BRIGHT MINDS BIOSCIENCES

Bright Minds Biosciences is a pharma organization headquartered in New York, USA. It trades on NYSE under ticker DRUG. Primary therapeutic focus areas include Cocaine-Related Disorders, Cocaine Dependence, Nicotine Depen

19 Vestry St, New York, NY 10013, US HQ
12 Employees
Public company Type
DRUG · NYSE Ticker
Company details
Status
Public
HQ
19 Vestry St, New York, NY 10013, US
Employees
12
Programs
1063
Drugs
444
Patents
57
Clinical program

Carvedilol

Phase 2 · small molecule · Cocaine-Related Disorders

Carvedilol for Cocaine-Related Disorders is a Phase 2 program (small_molecule) at BRIGHT MINDS BIOSCIENCES INC. with 1 ClinicalTrials.gov record(s).

← All BRIGHT MINDS BIOSCIENCES INC. projects Phase 2 small molecule completed

Internal code NIDA-09259-11

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
BRIGHT MINDS BIOSCIENCES INC.
Phase
Phase 2
Modality
small_molecule
Indication
Cocaine-Related Disorders
Status
completed
Trials
1